Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Description

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Conditions

Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors

Talk to us

Study Overview

On this page

Study Details

Study overview

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Condition
Non-small Cell Lung Cancer (NSCLC)
Intervention / Treatment

-

Contacts and Locations

Orange

UC Irvine/Chao Family Comprehensive Cancer Center, Orange, California, United States, 92868

Santa Monica

UCLA, Santa Monica, California, United States, 90404

Tampa

Moffitt Cancer Center, Tampa, Florida, United States, 33612

Baltimore

Johns Hopkins University, Baltimore, Maryland, United States, 21287

Boston

Dana Farber Cancer Institute, Boston, Massachusetts, United States, 02215

New York

Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States, 10016

New York

Memorial Sloan-Kettering Cancer Center, New York, New York, United States, 10021

New York

Columbia University, New York, New York, United States, 10032

Cincinnati

Christ Hospital Cancer Center, Cincinnati, Ohio, United States, 45219

Nashville

Sarah Cannon Research Institute, Nashville, Tennessee, United States, 37203

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).
  • * Received prior standard therapy appropriate for tumor type and stage
  • * Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • * Adequate organ function
  • * Primary central nervous system (CNS) tumors
  • * Active, untreated brain metastases
  • * Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
  • * History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Revolution Medicines, Inc.,

Revolution Medicines, Inc., STUDY_DIRECTOR, Revolution Medicines, Inc.

Study Record Dates

2026-06-30